Compared to Estimates, Health Catalyst (HCAT) Q2 Earnings: A Look at Key Metrics

Health Catalyst (HCAT) reported Q2 2025 revenue of $80.72 million, a 6.4% year-over-year increase that slightly beat the Zacks Consensus Estimate by 0.24%. EPS came in at $0.04, down from $0.12 year-ago, but exceeded the consensus estimate of $0.03 by 33.33%. Key segment performance included an 11% year-over-year increase in Technology revenue, while Professional Services revenue declined, though its adjusted gross profit surpassed analyst expectations. Despite beating some estimates, HCAT shares have returned -5.2% over the past month, underperforming the S&P 500's +1.2% gain.

Analysis

Health Catalyst (HCAT) presented a mixed financial picture for its second quarter of 2025, beating consensus estimates on both the top and bottom lines but revealing underlying weaknesses. Total revenue grew 6.4% year-over-year to $80.72 million, narrowly surpassing the $80.53 million estimate. While the reported EPS of $0.04 represented a significant 33.33% surprise over the $0.03 consensus, it marked a steep decline from the $0.12 reported in the prior-year quarter. A deeper look into segment performance shows a divergence: the Technology division drove growth with an 11% year-over-year revenue increase to $52.88 million, while the Professional Services division contracted, with revenue falling 1.5% to $27.85 million. Profitability signals were also conflicting, as the Technology segment's adjusted gross profit of $34.85 million missed analyst expectations, whereas the declining Professional Services segment's adjusted gross profit of $5.11 million substantially beat its forecast. This complex result is set against a backdrop of poor stock performance, with shares returning -5.2% over the past month, in stark contrast to the S&P 500's +1.2% gain, and a neutral Zacks Rank #3 (Hold) rating.

Key Decisions for Investors

• Investors should scrutinize the diverging performance between the high-growth Technology segment and the declining Professional Services segment, as future valuation depends heavily on the former's ability to drive overall profitability.
• The miss on adjusted gross profit for the Technology segment, despite its revenue growth, is a key concern, warranting close monitoring of margin trends in this critical business unit in subsequent quarters.
• Given the stock's recent underperformance and the sharp year-over-year decline in EPS, investors should weigh these negative factors against the headline beats, as the market appears to be focusing on the weaker fundamental signals.